Introduction
Candidiasis, especially that caused by Candida albicans, is extremely common; however, it is not clear why these usually harmless commensal organisms become pathogenic. Candidiasis can occur in most parts of the body. Infection is particularly common in young children and elderly people following antibiotic treatment. People with diabetes and suppressed immune systems are also vulnerable to candidiasis. Most infections are local, but for immune-suppressed patients they can become systemic and life-threatening, especially if they are infected with a drug-resistant strain. [1, 2, 3] The choice of antifungal agent used in the treatment of candidiasis is dependent upon the severity and nature of the infection. [4] In case of local infections, only topical therapy is preferred and in case of systemic infections, a combination of topical and systemic therapies is used as treatment regimen. [5] Itraconazole (ITZ), a broad-spectrum antimycotic triazole has been used for both prophylaxis and treatment of invasive fungal diseases, such as candidiasis and aspergillosis for the last two decades. ITZ is classified as a class II drug according to the Biopharmaceutical Classification System. It has an extremely low aqueous solubility (S<1 μg/ml) and poor dissolution rate in the gastrointestinal tract and hence low and variable bioavailability.
The present study involves formulation of Itraconazole lozenges for topical therapy of oropharyngeal candidiasis. Lozenges are the flavored medicated dosage forms intended to be sucked and held in the mouth or pharynx containing one or more medicaments usually in the sweetened base. Lozenges are intended to relieve oropharyngeal symptoms, which are commonly caused by local infections. Topical application of drug prevents several drug interactions. Lozenges are considered to be better delivery system as the effective concentrations of the drug can be maintained in the oral cavity for a prolonged period as the lozenge is sucked slowly in the mouth. [6, 7, 8, 9, 10] 
II.
Materials And Methods
Materials
Itraconazole was kindly supplied as a gift sample from Cornelius Pharmaceuticals (p) Ltd. Hyderabad, India; Sucrose, Gelatin, PEG 1500, Sodium lauryl sulphate by s d fine-chem Limited; Acacia, tragacanth, PEG 400, Sodium hydroxide, Potassium phosphate, monobasic by Finar chemicals Limited; PEG 4000 by Loba Chemie Pvt. Ltd. Sucralose by Natura. All other chemicals were of analytical grade. Itraconazole is soluble at acidic pH and has minimal solubility at neutral pH. While performing invitro drug release studies the amount of drug present in the sample could not be detected because of the solubility problem. Hence sodium lauryl sulphate (SLS) was added to increase the solubility of Itraconazole in pH 6.8 buffer.
Various concentrations like 0.1%, 0.5%, 1%, 1.5% and 2% were tried to optimize the concentration of SLS to be added.
Formulation of different types of Itraconazole lozenges

Formulation of compressed tablet lozenges
Compressed tablet lozenges were prepared by wet granulation method. Accurately weighed amount of Itraconazole was added in small parts to sucrose and mixed thoroughly. This was granulated using binder solution (different concentrations of gelatin, acacia and tragacanth). The granules obtained were passed through sieve #16 and then dried. The dried granules retained on the sieve #18, along with 15% fines were mixed with weighed amounts of lubricant and glidant and were compressed in machine with maximum force to obtain a compact flat faced tablet lozenges. Color and flavor were added to the binder solution. (TABLES 1-3) ( 
.2 Formulation of soft lozenges
 Hand-rolled lozenges The binders used in these lozenges were acacia, gelatin and tragacanth at different concentrations. The powdered sugar and drug were sifted together and sufficient binder solution was gradually added to make a mass of the proper consistency. The mass was rolled into the shape of a cylinder and cut into 10 even sections (approximately twice the length of the diameter). Allowed to air dry (TABLES 4-6). 
Evaluation and characterization
The prepared lozenges were evaluated for parameters like flow properties of granules, weight variation, hardness, friability, thickness and diameter, disintegration time, drug content uniformity and drug-excipient compatibility studies (FTIR).
Weight variation
The weight variation was conducted by weighing 20 lozenges individually and calculating the average weight and comparing the individual lozenges weight to the average value.
Hardness
The hardness (Kg/ cm 2 ) of the prepared lozenges was determined using Monsanto hardness tester.
Thickness and diameter
Control of physical dimensions of the tablet such as thickness and diameter is essential for consumer acceptance and tablet uniformity. The thickness and diameter of the tablet was measured using screw gauge. It is measured in mm.
Friability
Friability was determined using Roche friabilator. Speed of friabilator was set at 25 rpm. Pre-weighed tablets (6 tablets) were placed in the friabilator and it was subjected to 100 revolutions. The tablets were re-weighed and the percentage friability was calculated.
Drug content
Ten lozenges from each batch were selected and weighed individually and crushed in a mortar. Drug was extracted with 50 ml of methanol. The drug content was determined spectrophotometrically at 262 nm with blank lozenge extract as the reference.
Disintegration test
The disintegration time of lozenges were determined by USP Disintegration apparatus and disintegration time was noted in pH 6.8 phosphate buffer containing 2% SLS at 37ºC.
In vitro dissolution studies
In-vitro dissolution studies were carried out using USP dissolution test apparatus type II (paddle type) at 100 rpm and 37 ±0.5ºC. pH 6.8 buffer containing 2% SLS was used as dissolution medium for in vitro dissolution studies. A lozenge was placed in each flask of the dissolution apparatus and samples of 5ml were withdrawn at predetermined time intervals for 60 min. In order to maintain sink conditions, an equal volume of medium was replaced. The samples were analyzed by using UV-Visible spectrophotometer at 262 nm and percentage drug released was calculated. This experiment was done in triplicate and the average percentage release was calculated.
Drug-excipient compatibility studies (FTIR)
Fourier transform infrared analysis was conducted to study the drug-excipient interactions Samples were scanned in the range from 400-4000 cm -1 .The detector was purged carefully by clean dry helium gas to increase the signal level and reduce moisture.
Antimicrobial activity
This was determined in the agar diffusion medium employing Cup plate technique. Pure drug solution was used as standard. Drug extracted from formulations using methanol was used as test solution. The standard solution and the developed formulations (test solution) were taken into separate cups bored into sterile nutrient agar previously seeded with organism (Candida albicans). After allowing diffusion of solutions for two hours, the plates were incubated for 48 hrs at 25 ºC. The zone of inhibition (ZOI) was compared with that of the standard. The optimized formulation was tested in triplicate.
Stability studies
The stability studies of optimized formulations F2 and F48 were performed at 40°C±2°C/75±5% RH and 25ºC±2ºC/60±5%RH respectively for 3months. The formulations were examined visually for physical changes. The drug content was also determined at the end of every month for 3 months.
III.
Results And Discussion 3.1 Analytical method development 
Evaluation of lozenges
Compressed tablet lozenges
The prepared Itraconazole lozenges were evaluated for their weight variation, hardness, friability, drug content uniformity and disintegration time. The percentage weight variation was within the specified IP limits and varied between 0.98% and 1.21%. Hardness of the tablet was in the range of 5.5 kg/cm 2 to 13.5 kg/cm 2 . Friability was less than 1% in all the batches, which indicates the tablet's ability to withstand shock during handling. Drug content was found to be in the range of 91.07% and 97.01%. Disintegration time was found to be in the range of 35 min and 46 min. It is clear from the above results that the evaluated parameters were within the limits. (TABLE 10) 
Formulation, Evaluation And Characterization Of Itraconazole Lozenges
The prepared Itraconazole soft lozenges were evaluated for their weight variation, hardness, thickness, drug content uniformity and disintegration time. From the results obtained, it is clear that the physical parameters evaluated for different batches were within the specified IP limits. (TABLES 11-12) 
Drug-excipient compatibility studies
The IR spectrum of the formulation F2 and formulation F48 recorded by FTIR spectrometer which are compared with standard functional group frequencies of Itraconazole. The characteristic peaks of the optimized formulations followed the same trajectory as that of the drug alone with minor differences. Thus there may be no drug-excipient interactions.
Antimicrobial activity
The optimized formulations showed antifungal activity when tested microbiologically by the CupPlate technique using drug solution as standard. The results obtained are as shown in Fig. 5 3.2.6 Stability studies It was observed that there was no change in the physical appearance of the formulation. The drug content was analyzed and the results were found to be in the range within the limits as per IP and ICH guidelines. The stability data of formulation F2 and F48 are illustrated in the tables. As observed from the data shown in the tables, the formulations showed no significant changes in the drug content, hardness, friability and in vitro drug release profiles. Hence, it is confirmed that the formulations were stable at elevated temperatures.
(TABLES 14-16) 
IV. Conclusion
Rationale of the study was to develop Itraconazole lozenges for topical therapy of oropharyngeal candidiasis. Topical application of drug prevents several drug interactions and lozenge is a better delivery system as the effective concentration of drug can be maintained in the oral cavity for a more prolonged period of time. Different types of Itraconazole lozenges were formulated and the formulations were evaluated for weight variation, hardness, drug content uniformity and disintegration time. In vitro drug release studies were carried out using USP dissolution apparatus type II. Two formulations, F2 and F48 were optimized based on in vitro drug release studies. The optimized formulations were also subjected to drug-excipient interaction studies, microbial studies and stability studies.
The lozenges were optimized by all the above parameters and the following conclusions were made from the studies.
 No drug-excipient interactions were seen.  The formulations were stable for 3 months and no significant drug degradation was observed.  The formulations had sufficient antimycotic activity. It can be stated that the objective of the study was met. Itraconazole lozenges were successful in delivering the drug for topical application.
